Tags

Type your tag names separated by a space and hit enter

The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis.
Diagn Microbiol Infect Dis. 2007 Feb; 57(2):195-200.DM

Abstract

The Meropenem Yearly Susceptibility Test Information Collection program is a global study providing in vitro surveillance data on antimicrobial susceptibility in centers prescribing meropenem. This study summarizes data on the activity of meropenem and 5 comparators against 4022 clinical isolates from 7 centers in Spain (1999-2003). Those bacteria intrinsically resistant to meropenem were excluded. Among Enterobacteriaceae, 100% of Enterobacter spp., Citrobacter spp., and Serratia spp. were susceptible to meropenem. Escherichia coli and Klebsiella pneumoniae susceptibilities to carbapenems were 100% and > or =98%, respectively. Extended-spectrum beta-lactamase-producing Enterobacteriaceae were 3.8% of isolates, and all of them were susceptible to meropenem. Ciprofloxacin resistance in E. coli was around 20%. Meropenem and piperacillin/tazobactam were the most active agents against Pseudomonas aeruginosa. Acinetobacter baumannii were 61-90% susceptible to carbapenems, but only 6-21% susceptible to ciprofloxacin. In this period, around 100% of oxacillin-susceptible staphylococci were susceptible to meropenem. There was no significant decrease in susceptibility to the carbapenems throughout the 5-year period. The clinical use of meropenem in 7 Spanish centers did not increase bacterial resistance to this agent in the microorganisms evaluated.

Authors+Show Affiliations

Hospital Virgen Macarena-Seville, 41080 Seville, Spain. apascual@us.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17052882

Citation

Pascual, Alvaro, et al. "The Meropenem Yearly Susceptibility Test Information Collection Antimicrobial Susceptibility Program in Spain: a 5-year Analysis." Diagnostic Microbiology and Infectious Disease, vol. 57, no. 2, 2007, pp. 195-200.
Pascual A, Perea E, Alvarez M, et al. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis. Diagn Microbiol Infect Dis. 2007;57(2):195-200.
Pascual, A., Perea, E., Alvarez, M., Casal, M., Garcia de Lomas, J., Garcia Rodríguez, J. A., Martin, R., Soria, G., & Zapardiel, J. (2007). The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis. Diagnostic Microbiology and Infectious Disease, 57(2), 195-200.
Pascual A, et al. The Meropenem Yearly Susceptibility Test Information Collection Antimicrobial Susceptibility Program in Spain: a 5-year Analysis. Diagn Microbiol Infect Dis. 2007;57(2):195-200. PubMed PMID: 17052882.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis. AU - Pascual,Alvaro, AU - Perea,E, AU - Alvarez,M, AU - Casal,M, AU - Garcia de Lomas,J, AU - Garcia Rodríguez,J A, AU - Martin,R, AU - Soria,G, AU - Zapardiel,J, AU - ,, Y1 - 2006/10/18/ PY - 2006/01/16/received PY - 2006/07/25/revised PY - 2006/08/17/accepted PY - 2006/10/21/pubmed PY - 2007/6/22/medline PY - 2006/10/21/entrez SP - 195 EP - 200 JF - Diagnostic microbiology and infectious disease JO - Diagn. Microbiol. Infect. Dis. VL - 57 IS - 2 N2 - The Meropenem Yearly Susceptibility Test Information Collection program is a global study providing in vitro surveillance data on antimicrobial susceptibility in centers prescribing meropenem. This study summarizes data on the activity of meropenem and 5 comparators against 4022 clinical isolates from 7 centers in Spain (1999-2003). Those bacteria intrinsically resistant to meropenem were excluded. Among Enterobacteriaceae, 100% of Enterobacter spp., Citrobacter spp., and Serratia spp. were susceptible to meropenem. Escherichia coli and Klebsiella pneumoniae susceptibilities to carbapenems were 100% and > or =98%, respectively. Extended-spectrum beta-lactamase-producing Enterobacteriaceae were 3.8% of isolates, and all of them were susceptible to meropenem. Ciprofloxacin resistance in E. coli was around 20%. Meropenem and piperacillin/tazobactam were the most active agents against Pseudomonas aeruginosa. Acinetobacter baumannii were 61-90% susceptible to carbapenems, but only 6-21% susceptible to ciprofloxacin. In this period, around 100% of oxacillin-susceptible staphylococci were susceptible to meropenem. There was no significant decrease in susceptibility to the carbapenems throughout the 5-year period. The clinical use of meropenem in 7 Spanish centers did not increase bacterial resistance to this agent in the microorganisms evaluated. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/17052882/The_Meropenem_Yearly_Susceptibility_Test_Information_Collection_antimicrobial_susceptibility_program_in_Spain:_a_5_year_analysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(06)00325-7 DB - PRIME DP - Unbound Medicine ER -